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Background: As anti-malarial drug resistance escalates, new safe and effective medications are necessary to prevent
and treat malaria infections. The US Army is developing tafenoquine (TQ), an analogue of primaquine (PQ), which is
expected to be more effective in preventing malaria in deployed military personnel.
Methods: To compare the prophylactic efficacy of TQ and PQ, a transgenic Plasmodium berghei parasite expressing
the bioluminescent reporter protein luciferase was utilized to visualize and quantify parasite development in
C57BL/6 albino mice treated with PQ and TQ in single or multiple regimens using a real-time in vivo imaging
system (IVIS). As an additional endpoint, blood stage parasitaemia was monitored by flow cytometry. Comparative
pharmacokinetic (PK) and liver distribution studies of oral and intravenous PQ and TQ were also performed.
Results: Mice treated orally with three doses of TQ at 5 mg/kg three doses of PQ at 25 mg/kg demonstrated no
bioluminescence liver signal and no blood stage parasitaemia was observed suggesting both drugs showed 100%
causal activity at the doses tested. Single dose oral treatment with 5 mg TQ or 25 mg of PQ, however, yielded
different results as only TQ treatment resulted in causal prophylaxis in P. berghei sporozoite-infected mice. TQ is
highly effective for causal prophylaxis in mice at a minimal curative single oral dose of 5 mg/kg, which is a five-fold
improvement in potency versus PQ. PK studies of the two drugs administered orally to mice showed that the
absolute bioavailability of oral TQ was 3.5-fold higher than PQ, and the AUC of oral TQ was 94-fold higher than oral
PQ. The elimination half-life of oral TQ in mice was 28 times longer than PQ, and the liver tissue distribution of TQ
revealed an AUC that was 188-fold higher than PQ.
Conclusions: The increased drug exposure levels and longer exposure time of oral TQ in the plasma and livers of
mice highlight the lead quality attributes that explain the much improved efficacy of TQ when compared to PQ.
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The 8-aminoquinoline (8-AQ) anti-malarials, such as
primaquine (PQ), have attracted much interest as che-
motherapeutic and prophylactic agents against the liver
stages of Plasmodium vivax and Plasmodium falciparum
malaria parasites (Figure 1). The 8-AQs are the only
known class of drugs with activity against both P. vivax
hypnozoites and P. falciparum gametocytes. The World
Health Organization recommends PQ in combination
with chloroquine for the radical cure of P. vivax malaria,
although limited compliance with the 14-day dosing
regimen is known to impact effectiveness [1]. The cli-
nical value of this class is compromised by the toxic side
effects, however, which include methemoglobinaemia
and haemolytic anaemia in patients with deficiency in
glucose-6-phosphate dehydrogenase (G6PD) activity [2].
Tafenoquine (TQ) is a 5-phenoxyl derivative of PQ
with a long elimination half-life, which is under develop-
ment by the US Army and GlaxoSmithKline Pharmaceu-
ticals for treatment of relapsing P. vivax malaria and
malaria prophylaxis. TQ has been shown to have activity
against both the blood and liver stages of malaria. In
vitro and in vivo animal models have shown that TQ is
more potent and less toxic than PQ [3]. TQ has advan-
tages as a chemoprophylactic agent, which is needed
to address the problems of patient drug compliance,
tolerance, and efficacy in both semi-immune and non-
immune populations [4]. Phase I, II, and III clinical stu-
dies have shown that TQ is a safe, well-tolerated, and
highly effective oral chemoprophylactic agent for the
treatment of Plasmodium infections [5-7].
Given its long half-life of approximately 14 days, TQ
has the potential to address problems with patient com-
pliance during radical cure treatment of P. vivax, asFigure 1 Chemical structures of primaquine and tafenoquine.Phase II studies of TQ treatment of vivax infections have
shown that 1–3 days of treatment is effective to prevent
P. vivax relapse when used alone or in combination with
other anti-malarials [7,8]. In addition to effectiveness
against hypnozoites, TQ also has been shown to have
anti-gametocyte activity and long-acting blood stage ac-
tivity against multidrug resistant strains [5]. These are
valuable lead quality attributes that make TQ a poten-
tially important agent for P. falciparum eradication [9].
Early animal studies have demonstrated that TQ had
greater activity than PQ against the hypnozoite stages of
Plasmodium cynomolgi and had equivalent efficacy
against Plasmodium knowlesi liver stage parasites in rhe-
sus monkeys [2]. Other studies in rhesus monkeys have
shown that TQ is also more effective against the blood-
stage asexual parasites of P. cynomolgi, P. knowlesi and
Plasmodium fragile than PQ [10-12].
In vitro data have shown that TQ has from 4 to 100
times higher blood schizonticidal activity against cul-
tured parasites of Plasmodium berghei, Plasmodium
yoelii, and P. falciparum, including multi-drug-resistant
strains [13-16]. TQ has been shown to inhibit sporozoite
development in Anopheles stephensi mosquitoes that fed
on P. berghei infected mice [17]. Further study in rodent
malaria liver stage by real time in vivo imaging system
(IVIS) have shown that the prophylactic activity of TQ is
3–4 times higher than PQ against liver stage malaria
parasites administered subcutaneously [18]. The only
study of the liver stage effects of TQ on a human
Plasmodium species, P. vivax, demonstrated significant
sporontocidal activity of TQ against Anopheles dirus
mosquitoes infected with P. vivax [19]. An in vivo im-
aging of luciferase-expressing parasites was used to com-
pare the liver stage activity of TQ versus PQ in rodents
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luciferase-expressing P. berghei parasites is conducted by
using a sensitive camera to examine the luminescence
emitted from anesthetized infected mice injected IP with
luciferin. In vivo imaging has been successfully used to
study P. berghei [18,20-25] and P. yoelii [26-28], which
are commonly used to study the efficacy of agents
against liver-stage. The authors’ laboratory acquired a
luciferase-expressing P. berghei parasite from the MR4
repository, and this organism has used successfully to
examine the time course of P. berghei infection in ro-
dents, and the organ-specific activity associated with
malaria drugs that exhibit true liver stage activity.
As previously discussed, TQ has been shown to be
highly effective for both radical cure of relapsing malaria
and causal prophylaxis. Relatively few mechanism stud-
ies have systematically characterized the sporontocidal
property of oral TQ, however, compared to the current
standard of care, oral PQ. Literature citations have relied
on a single pharmacokinetic (PK) advantage of TQ’s lon-
ger half-life as a mechanism to explain enhanced liver
stage activity. In this study, the liver stage activity of TQ
and PQ in P. berghei infected mice was examined kine-
tically with a focus on prophylaxis of P. berghei sporo-
zoites infected mice during the malaria liver-stage by
using a modified real time imaging method. PK assays
were used to provide a systematic PK profile for both
drugs in mice to include 1) oral absolute bioavailability
of TQ and PQ; 2) drug distribution in liver tissue, which
is the target organ of both drugs; 3) drug elimination
half-lives in liver and plasma; 4) drug concentration ra-
tios of liver to plasma; and 5) total drug clearance.
Methods
Study drugs
TQ and PQ were formulated as a salt, but they were
dosed in this study per the base compound weights. The
bulk drug of TQ used for the test was synthesized for
WRAIR by Ash Stevens, Inc. (Detroit, MI) and had a
purity of > 99.8% by LC-MS/MS measurement.
Sporozoites, inoculation and viability check
Luciferase-expressing P. berghei ANKA sporozoites were
obtained from laboratory-reared female An. stephensi
mosquitoes from the Department of Mosquito Biology,
WRAIR. The mosquitoes were maintained at 18°C for
17 to 22 days after feeding on P. berghei malaria infected
Swiss ICR mice. Salivary glands were extracted from
malaria-infected mosquitoes and kept on ice in RPMI
medium with 1% mouse serum. Sporozoites will be
recovered by the method of Ozaki [29], and quantitated
using a haemocytometer. Sporozoites isolated from the
same batch of mosquitoes will be inoculated into
C57BL/6 albino mice on the same day to control forbiological variability in sporozoite preparations. Each
C57BL/6 mouse will be inoculated intravenously in the
tail vein with approximately 50,000 sporozoites sus-
pended in 0.1 mL volume on day 0. To ensure that ino-
culated sporozoites are viable following the isolation
procedure, they will be stained with a vital dye con-
taining fluorescein diacetate (50 mg/mL in acetone) and
ethidium bromide (20 μg/mL in phosphate-buffered
saline; Sigma Chemical Co., St. Louis, Mo.) and counted
in a haemocytometer. The viability of sporozoites ranged
from 87 to 100%.
Animals
Male 6-week-old C57BL/6 albino mice (NCI-Frederick,
MD) were used for malaria liver-stage in vivo imaging
assays, and male 7-week-old ICR mice (Charles River
Lab, MA) were used for the PK evaluations. On arrival,
the animals were acclimated for seven days in quaran-
tine. The animals were housed in a cage maintained in a
room with a temperature range of 64–79°F, 34–68% rela-
tive humidity and a 12-h light/dark cycles. Food and
water were provided ad libitum during quarantine and
throughout the study. The animals were fed a standard
rodent maintenance diet. All animal studies were per-
formed under IACUC approved protocols. These proto-
cols detail the experimental procedures and designs as
well as number of animals were used. All animal use,
care, and handling were performed in accordance with
the current “Guide for the Care and Use of Laboratory
Animals” (8th Edition, NIH, 2011) Science Education &
Strategic Communications Walter Reed Army Institute
of Research.
Test agent administration and sampling
Novel and control anti-malarials were administered or-
ally on days −1, 0, and 1 with respect to sporozoite in-
oculation. At 24, 48, and 72 hours post sporozoite
infection, all inoculated mice were tested using the IVIS
Spectrum instrument (Perkin Elmer, Hanover, MD). Ad-
ditionally, blood stage infections were measured by flow
cytometry. Positive and negative controls were used for
the IVIS calibration in each test.
Causal prophylactic effects and delay in onset of para-
sitaemia in animals treated with TQ and PQ (Figure 1)
were assessed in these experiments, which included
a positive control, 4-methyl-PQ. All dosing was con-
ducted based on the body weight at the time of prepar-
ation of the dosing solution. Both PQ and TQ were
dissolved in distilled water and administered intragastri-
cally with concentrations ranging from 1.25–25 mg/kg
body weight. A once-a-day, three-consecutive-day treat-
ment regimen (−1, 0, 1 day) was used in all assessments,
on the day before sporozoite challenge, the day of chal-
lenge, and the day after challenge. Each animal received
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tric feeder (18-gauge) to the designated recipient. Stock
solutions of test compounds were prepared fresh daily by
grinding the needed amount of drug in cold (4°C) 0.5%
(w/v) hydroxyethyl cellulose and 0.2% (v/v) Tween-80
(0.5% HECT) and diluting the resulting solution at vari-
able concentrations. C57BL/6 albino mice were challenged
intravenously with 50,000 luciferase-expressing P. berghei
sporozoites extracted from the salivary glands of heavily
infected An. stephensi mosquitoes. In vivo imaging was
performed at 24, 48, and 72 hours after infection. At day
5–30 after infection, the same mice were analysed for
blood stage infection by determination of the course of
parasitaemia of tail blood by flow cytometry using an
FC500 flow cytometer (Beckman-Coulter Co. CA). Blood
samples (3 μL each) for parasitaemia determinations were
collected on day 5 after inoculation and every other day
thereafter until a pair of positive parasitaemia was demon-
strated or for 30 days, then twice weekly for another
4 weeks if negative for parasites.
In vivo image system (IVIS)
In vivo imaging studies of bioluminescence activity from
luciferase expressing P. berghei infected mice were per-
formed using a Perkin Elmer IVIS Spectrum (Hanover,
MD). Mice were evaluated at 24, 48, and 72 hours post
sporozoite inoculation to determine liver- and blood-stage
malaria infection. Mice received 150 mg/kg luciferin (Gold
Biotechnology, St. Louis, MO) intraperitoneally in a vo-
lume not to exceed 150 μL. Three minutes post luciferin
administration the mice were anesthetized with inhaled
isoflurane. The mice were then positioned ventral side up
in the IVIS on a 37°C platform. The mice continue to re-
ceive isoflurane through nose cone delivery. The camera
exposure times utilized were 1 and 5 minutes for the 24,
48, and 72 hour time points with f-stop = 1 and large bin-
ning setting. Quantitative analysis of bioluminescence
emitted from whole bodies or region of intensity (ROI)
were determined by measuring the luminescence signal
intensity in photons/second using the ROI settings of the
Living Image® 3.0 software. The ROI, which measure-
ments were expressed in total flux of photons, was set to
measure the abdominal area at the location of the liver
from whole body imaging.
Flow cytometry (FCM)
At day 5–30 after infection, the same mice were analysed
for blood stage infections by quantitation of malaria para-
sites by flow cytometry (FCM). All FCM analyses were
carried out with a FC500 MPL flow cytometer (Beckman
Coulter, Fullerton, CA), which conducts five-colour ana-
lysis from either single or dual laser excitation. Infected
erythrocytes, uninfected erythrocytes, and leukocytes were
gated on logarithmic forward/side dot plots. Cells wereanalysed at an average rate of 2,000-3,000 erythrocytes/s.
Filters were placed before the green (FL-1) and red (FL-2)
photomultiplier tubes (PMTs) such that the green PMT
registered fluorescence emission between 520 and 555 nm,
and the red PMT measured emission greater than 580 nm.
A drop of blood (3 μL) from the mouse tail was
collected directly into 0.3 ml of 1% heparinized isotonic
buffer (PBS saline). In this study, 1 ml 0.04% of glutaralde-
hyde was used for fixation and the samples were then in-
cubated at 4°C for 60 minutes. The cells were centrifuged
at 450 × g for 5 min. The supernatant was removed by as-
piration, and the cells were re-suspended in 0.5 ml PBS
buffer supplemented with 0.25% (v/v) Triton X-100 for
10 minute incubation at room temperature. After centri-
fugation, the permeabilized cells were re-suspended in
0.5 ml of RNAse at 1 mg/ml concentrations and incubated
for at least 2 hours at 37°C to ensure complete digestion
of reticulocytes. Plasmodium berghei infection in mice re-
sults in anaemia which then results in reticulocytosis.
Therefore, high RNAse concentrations for digesting large
amounts of reticulocytes RNA were required for assess-
ment of parasitaemia in this mouse model. YOYO-1 dye
(from 1 mM stock solution in DMSO, as supplied by the
manufacturer) was diluted to 2500 ng/mL (100-fold) con-
centrations in PBS and 20 μL of YOYO-1 solution at
2500 ng/mL was added to 0.5 mL of sample to a final dye
concentration of 100 ng/ml of YOYO-1, which has been
shown to be optimal to discriminate infected erythrocytes
from the lowest (0.01%) to the highest parasitaemia counts
(74.0%) [30,31].
Pharmacokinetic (PK) studies
PK studies were performed using both intravenous (IV)
and intragastric (IG) administration. For each time point
to be acquired, three male ICR mice per time-point, aged
seven weeks, were dosed at either PQ or TQ at 5 mg/kg
(IV) or 20 mg/kg (IG). Drug vehicle for IV studies was
0.9% saline solution, and the formulated drugs were ad-
ministered in a volume of 100 μL/20 g of body weight. For
IG dosing, the drug vehicle was 0.5% HECT, administered
at 100 μL/20 g. At each time point, plasma and liver sam-
ples were collected. Whole blood was collected by cardiac
puncture. Blood samples were collected in lithium heparin
tubes within 0 h (baseline) prior to drugs administration
and at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, and 336 h after drug
administration. Following the separation of appropriate
aliquots, plasma was obtained from the whole blood via
centrifugation. All liquid and tissue samples were immedi-
ately preserved on dry ice and lately stored at −80°C until
analytical work was performed.
LC-MS/MS analysis
Sample was prepared by adding twice the normal vo-
lume of acetonitrile containing indomethacin internal
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trifugation for 5 minutes, and the supernatant was trans-
ferred to an autosampler injection vial prior to separation
by LC/MS/MS. Standard curve and quality control (QC)
samples were generated by spiking interference free
mouse plasma samples with known amounts of PQ, TQ
and IS. Standard curve, QC, and assay samples were pre-
pared and then 40 μL aliquots were injected into the LC/
MS/MS system for chromatographic separation and sub-
sequent mass spectrometric detection.
Blank liver homogenate was prepared by adding 5 mL of
water for each gram of liver, then the mixture was homog-
enized using an ultra-sonication probe (VCX 750, Sonics
& Materials, Inc., Newtown, CT). Plasma and liver homo-
genate standard curves were prepared via serial dilutions
from a high concentration value (generally 500 ng/mL)
through a series of 10–11 lower concentration values. The
serial dilutions for analysis also included the preparation
of 4–5 QC samples at a low range point and a high range
point (generally 10 ng/mL and 100 ng/mL, respectively).
Once the standard curve dilutions were prepared, a
100 μL aliquot was removed and extracted with 200 μL
acetonitrile. The extracted samples were centrifuged at
10,000 rpm for 10 min and the supernatant was removed
for analysis by LC-MS/MS. Sample drug concentrations
were first interpolated from the standard curve, then
multiplied by a factor of 6 to account for the drug levels
present in the liver prior to dilution with water for
homogenization.
Chromatography was performed using a Surveyor pump
(Thermo Scientific, Waltham, MA) with Waters XTerra
MS C18 50 mm × 2.1 mm id, 3.5 μm particle size columns
(Waters Corp., Milford, MA). Mobile phase consisted of a
water/0.1% formic acid (Solvent A)/acetonitrile/0.1% for-
mic acid (Solvent B) gradient. The gradient began at 2% B,
rose to 98% B from 1 min to 3.5 min, held steady for
2 min, then returned immediately to its starting com-
position and allowed to equilibrate for 1.5 min. Flow rate
was 300 μL/min. Samples were injected using an HTC
PAL autosampler (LEAP Technologies, Carrboro, NC).
Tandem mass spectrometry was performed using a TSQ
Quantum AM (Thermo Scientific).
PK parameter determination
Drug concentrations were generated for each sample
taken from animals dosed with both test drugs. A mea-
sured plasma and liver drug concentration vs. time curve
was produced, in graphic and tabular form, for each sub-
ject on both linear/linear and log/linear scales, for the
parent compound. Mean plasma drug concentration vs.
time curves were also prepared separately. For the deter-
mination of initial approach to PK parameters of TQ
and PQ in plasma and liver tissues after systemic appli-
cation, a non-compartmental analysis was performedusing Phoenix (version 6.1; Pharsight Corp., Mountain
View, CA). Maximum plasma and liver concentration
(Cmax), and time to maximum concentration (tmax) of TQ
and PQ were obtained from the plasma and liver drug
concentration-time curves. The elimination half-life (t1/2)
was calculated from In2/kel, which is the elimination rate
constant calculated from the log concentration-time plot.
The area under the curve (AUC) and the area under the
first moment curve (AUMC) were determined by the
linear trapezoidal rule with extrapolation to infinity based
on the concentration of the last time point divided by the
terminal rate constant. Mean clearance rate (CL) was de-
termined by dividing the dose by the AUCinf for intraven-
ous injection for plasma samples. Absolute bioavailability
was calculated by taking the dose-corrected area under
the curve (AUC) from non-intravenous dosing divided by
the AUC derived from intravenous dosing. Mean resi-
dence time (MRT) was determined by dividing the area
under the first moment curve (AUMC) by AUC. The vol-
ume of the central compartment (Vz) and volume of the
tissue compartment (Vz/F) were calculated as the product
of CL and MRT.
Data analysis
A Perkin Elmer In Vivo Imaging System (IVIS) Spectrum
was used to provide a quantitative evaluation at 24, 48,
and 72 hours post sporozoite inoculation to determine
compound activity against liver- and blood-stage para-
sites. In the in vivo imaging experiments, causal prophy-
laxis activity, sporontocidal activity, parasite clearance,
causal cure, delays in patency, and time to recrudescence
were calculated as described previously [31]. The mini-
mum curative dose (MCD100) in 100% animals was
defined as the lowest dose, which cured all animals (>5
animals) in a group at any time during the first 30 days
of the follow-up period. The data were generally found
to fit a normal distribution. Means and standard devia-
tions of photon measurement were calculated. Blood
stage infection was defined as two positive blood sam-
ples by flow cytometry, taken daily apart. The negative
blood samples were monitored until day 15 after inocu-
lation. Coefficients of variation were calculated as a per-
centage by dividing the standard deviation by the mean
value. Statistical analysis was conducted with Microsoft
Excel software by using a Student t test for dependent
samples to compare the means of paired and unpaired
samples between treatment groups.
Results
Real time in vivo imaging of liver-stage model in mice
Real time in vivo imaging to determine the timing and
level of luminescence measured from luciferase expres-
sion of sporozoites development in the liver was de-
scribed previously by Ploemen et al. [18] and Thiberge
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luciferase activity of infected sporozoites in liver cells.
Five mice per group were treated with or without dif-
ferent doses of prophylactic drugs starting one day be-
fore infection, the day during infection with luciferase-
sporozoites, and the last dose at one day after infection.
The test subjects were infected with 50,000 sporozoites
by intravenous injection in the tail vein and the lumines-
cence levels were determined 24, 48, and 72 hours post
infection.
Mean luminescence values (photon counts) collected
from liver location of untreated control mice were
2.07 × 106 photons/second (CV = 47.5%) at 24 hours and
35.48 × 106 photons/second (CV = 44.9%) at 48 hours. In
the untreated control animals, there was a strong increase
in bioluminescence signal at 48 hours, and the liver region
of intensity (ROI) was increased 17.2-fold when compared
to 24 hours subjects. The liver stage of P. berghei is
48 hours in duration, and no significant blood stageFigure 2 Representative in vivo images (IVIS) of luminescence shown
after injection of 5 × 104 sporozoites. Rainbow images show the relative
to high (yellow/red). Luminescence levels (photons/sec) of livers in whole m
daily for 3-consecutive-day on days −1, 0, 1, treated with tafenoquine (TQ)
sporozoite infection intravenously at day 0. Normally, P. berghei sporozoitesactivity was not observed after the 48 hour liver stage was
completed (Figure 2, right). At 72 hours, mean lumines-
cence signals of 127.67 × 106 photons/second (CV =
65.3%), could be detected only in the whole bodies of
untreated mice, which was 3.6 times higher than the lu-
minescence measured at 48 hours, suggesting that the
majority of the increase in luminescence observed was
produced by blood stage P. berghei parasites [18]. This is
consistent with the known 48-hour duration of the liver
stage of P. berghei malaria model where parasites invade
erythrocytes after the rupture of liver schizonts 48 hours
post inoculation.
Prophylactic efficacy of PQ and TQ after daily dosing for
3 days
Analysis of the inhibition of in vivo liver stage develop-
ment by PQ and TQ was assessed by measuring lumines-
cence using a Perkin Elmer Spectrum In Vivo Imaging
System (IVIS). Mice were treated with daily doses of PQin the livers of live C57BL/6 albino mice at different time points
levels of luminescence ranging from low (blue), to medium (green),
ice at 24, 48 and 72 hour time points following intragastric dosing
at a dose of 5 mg/kg (TQ, left) and vehicle control (VC, right) after
reside in the mouse liver for 44–52 hours post-infection (n = 4).
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daily doses of TQ at 1.25, 2.5, 5, and 10 mg/kg body
weight for three consecutive days (Table 1, Figure 2, left).
In mice treated with 2.5 mg/kg body weight of TQ, 2
out of 5 mice showed a low level of luminescence ranging
between 0.09 × 105 and 0.35 × 105 photons/second at
24–48 hours while the remaining 3 mice were negative.
Two of these five mice developed a blood stage para-
sitaemia that was delayed by 2–4 days compared to the
control mice. In 5 of 10 animals treated with 10 mg/kg
PQ, a low level of luminescence was observed at 48 hours
(0.66 × 105 photons/sec) while the remaining 5 mice were
negative. Five of these ten mice developed a blood stage
parasitaemia that was delayed by 2–4 days compared to
the control mice. All mice treated with 5 mg/kg of TQ
and 25 mg/kg of PQ were luminescence negative during
the observation period from 24 to 48 hours after infection,
and none of these animals developed blood stage infec-
tion, suggesting that TQ is 5 times more potent for causal
prophylaxis as PQ in this rodent malaria model. The
complete inhibition of liver stage development by PQ at
doses of 25 mg/kg body weight and higher and by TQ
at doses of 5 mg/kg body weight and higher are in
agreement with the inhibitory doses reported in the
literature [12-15,18].
Prophylactic efficacy of single doses of PQ and TQ
Mice treated with single oral doses of TQ at 5 mg/kg
one day prior to infection showed causal prophylaxis re-
sults similar to those obtained through multiple doses of
TQ at lower concentrations. A detectable luminescence
signal in the liver was observed in mice treated with
5 mg/kg of TQ 24 and 48 hours after infection, but no
blood stage parasitaemia was noted up to 30 days post
infection suggesting that the suppressive effect of TQ
against liver stage parasite growth and curative activity
in the blood stage was due to a single oral dose of TQ
(Table 1). In the group treated with a single oral dose of
PQ at 25 mg/kg, high levels of luminescence and no
suppression of signal were observed in the livers of mice
after 24 hours suggesting incomplete inhibition of para-
site growth (Table 1). In addition, analysis of these mice
5–30 days after infection showed severe parasitaemia in
peripheral blood, suggesting that the single dose failure
of PQ may be due to its short half-life.
PK and bioavailability of intravenous and orally dosed PQ
or TQ in mice
The individual computer fitted plasma concentration-
time curves following single intragastric administration
of PQ in mice are shown in Figure 3. The PK parameter
estimates in plasma derived from animals dosed at
5 mg/kg PQ intravenously and 20 mg/kg intragastrically
are summarized in Table 2. The mean Cmax and AUCinfof PQ was 1.21 μg/ml and 1.20 μg · h/ml, respectively,
following single dose IV administration. The mean elim-
ination half-life of intravenous PQ was 0.63 hours and
the total clearance rate was 4.19 liter/h/kg.
Oral PQ showed very rapid absorption and reached a
plasma peak concentration (Tmax) at 0.50 hours. The
mean Cmax and AUCinf of PQ was 0.53 μg/ml and
1.31 μg · h/ml, respectively, following a single dose orally
administered. The mean elimination half-life of oral PQ
was shown to be 1.84 hours and the total clearance rate
was calculated to be 57.94 liter/h/kg. The mean absolute
bioavailability of oral PQ was calculated to be 28.32%,
and this calculation was also based on the data derived
from intravenous dosing.
The PK parameters assessed in animals after doses of
5 mg/kg TQ intravenously and 20 mg/kg intragastrically
are summarized in Table 2. The mean Cmax and AUCinf
of TQ was shown to be 0.66 μg/ml and 30.14 μg · h/ml,
respectively, following IV administration. The mean
elimination half-life of IV TQ was 66.28 hours and the
total clearance rate was 0.17 liter/h/kg. TQ was shown
to be absorbed very slowly with a Tmax of 11.33 hours.
The results demonstrated that the mean Cmax and
AUCinf of TQ was 2.04 μg/ml and 139.18 μg · h/ml,
respectively, following oral administration. The mean
elimination half-life of TQ was 50.87 hours and the total
clearance rate was 0.15 liter/h/kg. The mean absolute
bioavailability of oral TQ was calculated to be 100.77%
in mice, and this calculation was also derived from the
data derived from intravenous dosing.
In comparison to the oral PK plasma parameters
shown, oral TQ has an absorption rate that is 22.7-fold
slower than PQ in mice. The Cmax and AUCinf of oral
TQ were approximately 4-fold and 94-fold, respectively,
higher than that of oral PQ. The elimination half-life of
oral TQ was shown to be approximately 28-fold longer
and the elimination clearance was shown to be 370-fold
slower than oral PQ. The mean absolute bioavailability
of oral TQ was 3.5-fold greater than oral PQ.
Liver distribution of intravenous and oral PQ or TQ in
mice
In this study, the parasite drug targets are inside hepa-
tocytes and, therefore, the PK profile of PQ and TQ in
the liver tissue is important. The liver tissue distribution
of PQ and TQ was analysed, and the PK parameter esti-
mates in the livers of mice dosed with PQ intravenously
at 5 mg/kg and intragastrically with PQ at a dose of
20 mg/kg are summarized in Table 2. The mean Cmax
and AUCinf of PQ was 3.99 μg/g and 6.14 μg · h/g, re-
spectively, following a single IV administration of PQ.
The ratio of the liver AUC to the plasma AUC in ani-
mals dosed with PQ intravenously was 3.91. The mean
elimination half-life of PQ in the liver was 1.32 hours
Table 1 The causal prophylactic activities of tafenoquine (TQ) and primaquine (PQ) by using real time in vivo image system (IVIS) following single dose (−1 or
0 day after inoculation) or daily oral administrations for 3 days multiple doses (−1, 0, and 1 day after infection) against challenge with 50,000 sporozoites of









Suppression rate (%) IVIS* Blood
Infection
by FCM*
Number of C57BL/albino mice
Delay in patency




Tafenoquine 10 3 days −1, 0, 1 100 100 100 0/5 5 5 5/5 - Full CP
5 3 days −1, 0, 1 90.4 100 100 0/13 13 13 13/13 - Full CP
2.5 3 days −1, 0, 1 100 100 100 2/5 5 3 3/5 - Partial CP
1.25 3 days −1, 0, 1 84.7 92.3 98.9 4/5 5 1 1/5 2,4,4,7 Suppression
5 Single −1 68.7 98.6 100 0/10 10 10 10/10 - Full CP
5 Single 0 66.0 91.1 98.5 4/5 5 1 1/5 4,2,4,9 Partial CP
Primaquine 25 3 days −1, 0, 1 100 100 100 0/10 10 10 10/10 - Full CP
20 3 days −1, 0, 1 100 100 100 1/10 10 9 9/10 6 Partial CP
15 3 days −1, 0, 1 100 100 100 4/20 20 16 16/20 2,2,2,1 Partial CP
10 3 days −1, 0, 1 100 97.6 100 5/10 10 5 5/10 2,4,2,2,4 Partial CP
5 3 days −1, 0, 1 82.4 77.5 89.4 5/5 5 0 0/5 2,2 Suppression
25 Single −1 45.7 0 0 5/5 5 0 0/5 - Suppression
25 Single 0 11.2 0 0 5/5 5 0 0/5 - Suppression
*The infection was determined by recording the onset of IVIS for liver stage and parasitaemia for blood stage by using a flow cytometry system (FCM).















Figure 3 Individual plasma concentration-time profiles of tafenoquine (TQ, triangle markers) and primaquine (PQ, circle markers)
measured by LC/MS/MS and computer fitted curves for TQ (solid line) and PQ (dashed line) at single intragastric dosage of 20 mg/kg
in mouse plasma (top) and liver (bottom) (n = 3).
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the PK parameters derived showed a mean Cmax and
AUCinf of 8.15 μg/g and 27.67 μg · h/g, respectively, fol-
lowing a single oral dose of PQ. The ratio of the liver
AUC to the plasma AUC in animals dosed with PQ or-
ally was 22.26. The mean elimination half-life of PQ in
liver was shown to be 4.28 hours following oral dosing.
Following TQ administration, the PK parameters de-
rived showed a mean Cmax and AUCinf of 44.76 μg/g and2544.96 μg · h/g, respectively, following a single IV ad-
ministration of TQ. The ratio of the liver AUC to the
plasma AUC in animals dosed with TQ intravenously
was 87.24. The mean elimination half-life of TQ in the
liver was shown to be 70.02 hours following IV injection.
After oral administration of TQ, the PK parameters
derived showed a mean Cmax and AUCinf of 56.90 μg/g
and 5391.86 μg · h/g, respectively, following single oral
administration of TQ. The ratio of the liver AUC to the
Table 2 Pharmacokinetic comparison of tafenoquine (TQ) and primaquine (PQ) in plasma and liver tissue following
single intravenous at dose of 5 mg/kg and intragastric at dose of 20 mg/kg administrations in male mice (n = 3)
PK parameters
Tafenoquine (TQ) Primaquine (PQ)
Plasma Liver Plasma Liver
Intravenous (5 mg/kg)
Cmax (μg/mL or g) 0.66 ± 0.13 44.76 ± 29.95 1.21 ± 0.21 3.99 ± 0.53
Tmax (hours) 1.36 ± 1.11 3.69 ± 2.29 0.08 ± 0.0 0.39 ± 0.53
AUClast (μg · h/mL or g) 29.63 ± 6.74 2493.82 ± 1361.10 1.20 ± 0.13 6.06 ± 1.39
AUCinfininty (μg · h/mL or g) 30.14 ± 6.65 2544.96 ± 1348.03 1.26 ± 0.14 6.14 ± 1.38
t1/2 elimination (h) 66.28 ± 10.32 70.02 ± 4.35 0.63 ± 0.08 1.32 ± 0.06
Vz (liter/kg) 16.76 ± 6.44 - 3.85 ± 0.71 -
Cl (liter/h/kg) 0.17 ± 0.04 - 4.19 ± 0.42 -
MRT (h) 55.92 ± 3.86 66.11 ± 19.19 0.68 ± 0.02 1.27 ± 0.11
AUCinf ratio (liver/plasma) - 87.24 ± 44.29 - 3.91 ± 0.54
Intragastric (20 mg/kg)
Cmax (μg/mL) 2.04 ± 0.59 56.90 ± 26.09 0.53 ± 0.07 8.15 ± 0.29
Tmax (hours) 11.33 ± 5.37 1.17 ± 0.76 0.50 ± 0.0 0.50 ± 0.0
AUClast (μg · h/mL) 137.91 ± 24.38 5140.52 ± 1794.60 1.26 ± 0.40 27.45 ± 1.84
AUCinfininty (μg · h/mL) 139.18 ± 24.92 5391.86 ± 1898.51 1.31 ± 0.41 27.67 ± 1.75
t1/2 elimination (h) 50.87 ± 4.23 75.48 ± 12.06 1.84 ± 0.45 4.28 ± 1.30
Vz (liter/kg) 10.60 ± 1.22 - 154.66 ± 61.83 -
Cl (liter/h/kg) 0.15 ± 0.03 - 57.94 ± 20.52 -
MRT (h) 62.08 ± 2.30 88.67 ± 12.98 2.28 ± 0.10 4.49 ± 0.25
AUCinf ratio (liver/plasma) - 48.91 ± 22.67 - 22.26 ± 6.73
Absolute bioavailability (%) 100.77 ± 37.49 28.32 ± 6.93
Vz = Volume of distribution based on the terminal phase; MRT =mean residence time, D = Day.
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The mean elimination half-life of TQ in liver was shown
to be 75.48 hours following oral dosing.
In comparison to the liver distribution of oral PQ, the
Cmax and AUCinf of orally dosed TQ were approximate
7-fold and 195-fold, respectively, much higher than that
of PQ in liver tissue. The elimination half-life of oral TQ
was estimated to be 17.6-fold longer than the elimi-
nation half-life of oral PQ in the liver.
Discussion
The screening and identification of agents that inhibit
Plasmodium development in the liver is considerably
more complex when compared to the very simple process
of screening small molecules for inhibitory activity against
blood-stage parasites. Quantitative analysis of liver stage
development in small laboratory animals, in vivo, is ham-
pered by the low levels of parasite infection as well as the
complicated, time consuming and expensive traditional
methods required to monitor parasite development, such
as RT-PCR, RNA hybridization or direct counting of liverstages parasites. In vivo imaging is a technique that cap-
tures light emitted by the reaction of luciferase and its
substrate luciferin, and this technique has been success-
fully used to study P. berghei [18,20-25] and P. yoelii
[26-28] liver stage infections, which were commonly used
to study the efficacy of agents against liver-stage Plasmo-
dium parasites. The addition of flow cytometric mo-
nitoring of blood stage parasites using the YOYO-1
intercalating dye [30,31] provides a means of completely
monitoring all aspects of the parasite life cycle in a rodent,
from sporozoite infection to development of mature blood
stage parasites.
To determine the timing and level of luminescence du-
ring P. berghei sporozoite development in the livers of in-
fected rodents, groups of mice (n = 5) were infected
intravenously with different numbers of sporozoites ran-
ging from 5 × 103 to 1 × 105. Luciferase activity in the ani-
mals was visualized by whole body imaging using the IVIS
Spectrum imaging system at 24, 48 and 72 hours after in-
fection. In control, uninfected mice, luminescence values
ranged between 1 × 102 and 1 × 103 photons/second. In
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and 1 × 105 sporozoites), all mice showed luminescence
levels significant above background at 24 hours with lumi-
nescence activity of 2.1 × 106 and 5.3 × 106 photons/sec-
ond, respectively. Mice infected with 2.5 × 104 or fewer
sporozoites showed a signal above background in only a
few animals at 24 hours. In all infected mice there was a
strong increase (6 – 17 fold) in bioluminescence signal at
48 hours. Therefore, 5 × 104 sporozoites is the minimum
sporozoite infectious burden required to induce lumines-
cence levels above background in 100% of the C57BL/6
albino mice tested. After 48 hours, luminescence signals
could be detected in the whole body of infected animals,
resulting from parasites that had invaded erythrocytes
after the rupture of the liver schizonts. Based on these ob-
servations, a window of luminescence intensities between
24 and 48 hours was determined in subsequent experi-
ments in mice infected with a constant number of 5 × 104
P. berghei sporozoites to test for liver-stage inhibition of
drugs.
In vivo assessment of drug efficacy against liver stage
Plasmodium parasites through in vivo imaging offers
clear advantages over standard methods of RT-PCR
analysis of dissected livers or through analysis of the
dynamics of blood stage infections examined subse-
quent to liver-stage infection. In vivo imaging is simple
and rapid and allows, within the same animal, measure-
ment of both the specific inhibition of liver stage devel-
opment by a small molecule and subsequent effects on
blood stage parasites. In vivo imaging analysis does not
require sacrificing experimental animals and thereby re-
duces the number of animals required for experimenta-
tion since multiple measurements can be made in the
same animal over time. Furthermore, in vivo imaging
also has the advantage that it minimizes the biological
variation within the study [24,28] as the in vivo analysis
of PQ and TQ liver stage efficacy was performed with
mice that were infected by intravenous injection of spo-
rozoites. All the control mice in these experiments (i.e.
infections in the absence of drug) injected intravenously
with sporozoites showed strong luminescence signals at
24 and 48 hours after infection. Complete inhibition of
signal in animals treated with PQ and TQ was observed
at intragastric doses of 25 mg/kg and 5 mg/kg, respec-
tively, which correspond to liver-stage inhibitory con-
centrations reported in the literature for primaquine
and tafenoquine treated subcutaneously with drug [18].
In conclusion, quantitative analysis of liver stage devel-
opment by real-time imaging should greatly aid the de-
velopment of drugs that act against the liver stages of
Plasmodium parasites.
PQ and TQ themself are generally believed unlikely to
be the clinically active form of the drug, because they
have similar multiple pathways and are extensivelymetabolized and less active than some of its metabolites
or derivatives in in vitro models [16,32]. Determination
of metabolic pathways in vivo that lead to efficacy is dif-
ficult, because there is no in vitro model of hypnozoites
within liver cells with which to evaluate efficacy. There-
fore, currently, the liver-stage efficacy was likely relating
to the PK concentrations of the parent drug of PQ and
TQ. The absorption rate (Tmax) of 11.33 hours observed
in animals treated with TQ suggests a slow absorption,
which implies a prolonged period of absorption in the gut.
Dissolution studies of TQ in simulated gastric fluid dem-
onstrate complete dissolution within 30 minutes [33].
Thus, the long apparent absorption phase may be due to a
distal GI absorption site combined with slow clearance of
TQ as Tmax is a function of both absorption and elimin-
ation rates. PQ is well absorbed from the gastrointestinal
tract with peak plasma levels attained within 5 minutes in
mice. TQ was found to be slowly but extensively metabo-
lized [33]. TQ has been shown to be eliminated via biliary
excretion with enterohepatic recirculation, but it is not
eliminated in the urine. PQ is similarly extensively and
rapidly metabolized with less than 1% of the dose excreted
as unchanged drug in the urine [33]. In this study, the
clearance (CL) of TQ was only 0.15 L/hours/kg (3% of the
hepatic blood flow), while PQ has a much more rapid
clearance of 57.94 L/hours/kg.
TQ has a 3.5-fold higher bioavailability was observed
following oral administration than oral PQ. Also, TQ
has a half-life that is more than 28 times longer was
noted than PQ. Figure 3 illustrates the effect of this
difference in half-lives between these two 8-aminoqui-
nolines. A single 20 mg/kg dose of TQ results in easily
quantifiable concentrations for more than two weeks.
However, a single 20 mg/kg dose of PQ results in no
detectable concentrations within 1 day after dosing.
Modeling of TQ, on the other hand, is best described by
a two-compartment model. This kinetic difference re-
sults in more prolonged, high concentrations of TQ in
the blood. These properties of TQ provide an advantage
over PQ in that they may permit long-term dosing for
prophylaxis and short-term or single dose therapy for
terminal eradication or radical cure of P. vivax malaria,
which will likely result in improved compliance and en-
hanced effectiveness.
In this study, TQ was found to be 5-fold more potent
than PQ as a liver schizonticides. This may be explained
in part by its full bioavailability, accumulation in the
blood and hepatocytes, prolonged elimination, and its
longer half-life, in addition to difference in intrinsic
activity. PQ, on the other hand, does not accumulate
inside blood and liver cells [33]. The increased drug
exposure levels and longer exposure time of oral TQ in
the plasma and livers of mice highlight the reasons for
its enhanced anti-malarial activity.
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